- Trials with a EudraCT protocol (297)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
297 result(s) found for: Relapsing-remitting.
Displaying page 8 of 15.
EudraCT Number: 2017-000426-35 | Sponsor Protocol Number: 1.0 | Start Date*: 2018-04-17 | ||||||||||||||||
Sponsor Name:Medical University of Vienna - Department of Neurology | ||||||||||||||||||
Full Title: Efficacy of Rituximab at low doses in Multiple Sclerosis – A prospective, randomized, double-blind, active controlled, pilo trial | ||||||||||||||||||
Medical condition: Relapse Remitting Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005003-24 | Sponsor Protocol Number: 109MS202 | Start Date*: 2015-06-01 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years | ||||||||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: LV (Completed) DE (Completed) CZ (Completed) BG (Completed) PL (Completed) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017490-38 | Sponsor Protocol Number: 101MS205 | Start Date*: 2010-05-03 | |||||||||||
Sponsor Name:Biogen Idec | |||||||||||||
Full Title: Randomized Treatment Interruption of Natalizumab | |||||||||||||
Medical condition: Natalizumab is a highly efficacious therapy used in the treatment of patients with relapsing multiple sclerosis (MS). This is a prospective randomized study in subjects with relapsing forms of MS w... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005746-15 | Sponsor Protocol Number: MN43964 | Start Date*: 2022-08-05 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis | ||||||||||||||||||
Medical condition: Primary Progressive Multiple Sclerosis (PPMS) Relapsing Multiple Sclerosis (RMS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: EE (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) LT (Trial now transitioned) NO (Completed) SK (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) LV (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) HR (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004562-22 | Sponsor Protocol Number: 109MS416 | Start Date*: 2015-06-10 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with M... | ||||||||||||||||||
Medical condition: Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) IT (Prematurely Ended) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-003930-16 | Sponsor Protocol Number: SIMCOMBIN | Start Date*: 2006-01-19 | |||||||||||
Sponsor Name:Biogen Idec A/S | |||||||||||||
Full Title: A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Mu... | |||||||||||||
Medical condition: Patients with definite relapsing-remitting multiple sclerosis who have never received treatment with interferons or glatiramer acetate, who meet all the criteria for inclusion and none of the exclu... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001362-25 | Sponsor Protocol Number: RAM-MS | Start Date*: 2018-05-02 | |||||||||||
Sponsor Name:Helse Bergen HF, Haukeland University Hospital | |||||||||||||
Full Title: Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis | |||||||||||||
Medical condition: Relapsing remitting multiple sclerosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001895-40 | Sponsor Protocol Number: 109MS406 | Start Date*: 2014-05-02 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Phase 4, Randomized, Double-Blind Study with a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects with Relapsing-Remitting Multiple Sclerosis Treated with Te... | ||||||||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-014724-32 | Sponsor Protocol Number: SABA | Start Date*: Information not available in EudraCT |
Sponsor Name:University Medical Center Eppendorf | ||
Full Title: SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS): A MRI-CONTROLLED, MULTICENTER, BASELINE-TO-TREATMENT, 32-WEEK... | ||
Medical condition: Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001253-13 | Sponsor Protocol Number: ROCHIMS | Start Date*: 2017-08-23 |
Sponsor Name:UZ Brussel | ||
Full Title: Does cerebral hypoperfusion play a role in reduced axonal metabolism and clinical disability in patients with multiple sclerosis ? | ||
Medical condition: Patients suffering relapsing- remitting multiple sclerosis will be investigated in this study, with an EDSS score less or equal to 4.0. Patients must be older than 18 years old. There must not be a... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002566-13 | Sponsor Protocol Number: NEXT-MS | Start Date*: 2019-12-19 | |||||||||||
Sponsor Name:Amsterdam University Medical Center | |||||||||||||
Full Title: Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis | |||||||||||||
Medical condition: Relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000516-22 | Sponsor Protocol Number: 800MS301 | Start Date*: 2019-07-08 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3- Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 ... | ||||||||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Not Authorised) EE (Prematurely Ended) HU (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000922-12 | Sponsor Protocol Number: TV44400-CNS-40083 | Start Date*: 2016-01-04 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries, Ltd | |||||||||||||
Full Title: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous... | |||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) DE (Completed) IE (Completed) PL (Completed) FI (Completed) ES (Completed) HR (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005148-28 | Sponsor Protocol Number: 25643 | Start Date*: 2005-05-26 | |||||||||||
Sponsor Name:Merck Serono International S.A. | |||||||||||||
Full Title: A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) DK (Completed) EE (Completed) CZ (Completed) BE (Completed) IT (Completed) AT (Completed) SK (Completed) LT (Completed) DE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002648-10 | Sponsor Protocol Number: 7109 | Start Date*: 2019-04-15 | |||||||||||
Sponsor Name:Hôpitaux Universitaires de Strasbourg | |||||||||||||
Full Title: TestOsterone TreatmEnt on neuroprotection and Myelin repair in Relapsing Remitting Multiple Sclerosis | |||||||||||||
Medical condition: Relapsing Remitting Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000150-31 | Sponsor Protocol Number: ET.ST.02/10MP | Start Date*: 2011-04-13 | ||||||||||||||||||||||||||
Sponsor Name:FONDAZIONE DON CARLO GNOCCHI ONLUS | ||||||||||||||||||||||||||||
Full Title: EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY. | ||||||||||||||||||||||||||||
Medical condition: Multiple Sclerosis patients | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001224-22 | Sponsor Protocol Number: 215MS202 | Start Date*: 2017-12-28 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as ... | ||||||||||||||||||
Medical condition: Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) BE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005989-37 | Sponsor Protocol Number: 308841 | Start Date*: 2006-03-29 |
Sponsor Name:Schering Oy | ||
Full Title: CogniMS: observational study to assess cognition in patients with early Multiple Sclerosis | ||
Medical condition: Observational Study to assess cognition in patients with early Multiple Sclerosis. Relapsing-Remitting MS-patients diagnosed within 2 years and who have started the Betaferon treatment (interferon-... | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004533-32 | Sponsor Protocol Number: 109MS305 | Start Date*: 2014-04-28 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of BG00012 in Subjects From the Asia Pacific Region and Other Countries With Relapsing-Remitting Multiple Scle... | ||||||||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003484-30 | Sponsor Protocol Number: CFTY720DES03 | Start Date*: 2011-10-26 |
Sponsor Name:Novartis Farmacéutica S.A. | ||
Full Title: A multi-centre, open-label, non-randomised, parallel group clinical trial to assess the efficacy of fingolimod in naïve patients versus fingolimod in patients previously treated with interferons or... | ||
Medical condition: Multiple Sclerosis relapsing-remitting course | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
